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Abstract: Background: The epidemiologic utility of STARHS hinges not only on producing accurate estimates of HIV
incidence, but also on identifying risk factors for recent HIV infection.
Methods: As part of an HIV seroincidence study, 800 Rwandan female sex workers (FSW) were HIV tested, with those
testing positive further tested by BED-CEIA (BED) and AxSYM Avidity Index (Ax-AI) assays. A sample of HIVnegative (N=397) FSW were followed prospectively for HIV seroconversion. We compared estimates of risk factors for:
1) prevalent HIV infection; 2) recently acquired HIV infection (RI) based on three different STARHS classifications
(BED alone, Ax-AI alone, BED/Ax-AI combined); and 3) prospectively observed seroconversion.
Results: There was mixed agreement in risk factors between methods. HSV-2 coinfection and recent STI treatment were
associated with both prevalent HIV infection and all three measures of recent infection. A number of risk factors were
associated only with prevalent infection, including widowhood, history of forced sex, regular alcohol consumption, prior
imprisonment, and current breastfeeding. Number of sex partners in the last 3 months was associated with recent infection
based on BED/Ax-AI combined, but not other STARHS-based recent infection outcomes or prevalent infection. Risk
factor estimates for prospectively observed seroconversion differed in magnitude and direction from those for recent
infection via STARHS.
Conclusions: Differences in risk factor estimates by each method could reflect true differences in risk factors between the
prevalent, recently, or newly infected populations, the effect of study interventions (among those followed prospectively),
or assay misclassification. Similar investigations in other populations/settings are needed to further establish the
epidemiologic utility of STARHS for identifying risk factors, in addition to incidence rate estimation.

Keywords: HIV/AIDS, incidence, cross-sectional surveys, prospective studies, risk factors, Rwanda.
INTRODUCTION
Reliable information on HIV incidence is critical to
public health practitioners and policymakers working in HIV
prevention in order to identify target populations, evaluate
the impact of HIV prevention interventions, and identify
important trends in dynamic epidemics [1]. Data on risk
factors for incident HIV infection help identify at-risk subgroups in immediate need of primary prevention
interventions [2, 3]. Despite these important applications,
data on HIV incidence rates and risk factors are scant,
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especially in sub-Saharan Africa where the majority of new
HIV infections are occurring [4, 5], and where most
information on risk factors is derived from HIV prevalence
data, such as from the Demographic and Health Surveys
(DHS) [6]. Key public health agencies, including the World
Health Organization and US Centers for Disease Control and
Prevention, have begun recommending strengthening of HIV
incidence surveillance systems at the country and regional
levels [7-11].
The Serologic Testing Algorithm for Recent HIV
Seroconversion (STARHS) is a laboratory test-based
approach that offers a promising alternative to prospective
incidence measurement for incidence surveillance.
Laboratory assays used under STARHS, such as the BEDCEIA (BED) [12] and AxSYM Avidity Index method (AxAI) [13], exploit immunologic properties of early HIV
infection, such as development of HIV antibodies, to
distinguish recent infections (RI) from long-term infections
2012 Bentham Open
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(LTI) in HIV-positive persons, enabling estimation of
incidence in a cross-sectional sample of HIV-positive and
negative individuals [9, 10, 14-24]. Further, if demographic
and behavioral data are collected alongside biologic samples
for STARHS testing, risk factors for RI, as distinguished
from prevalent infection, can be identified.
The potential public health impact of the STARHS
method lies in its epidemiologic utility, which we define as
the ability of an assay or algorithm to: 1) accurately estimate
HIV incidence rates, and 2) distinguish risk factors for RI
from LTI when such differences exist, within a population
sample of individuals tested for HIV and interviewed for
behavioral and other risk factor information. The latter is
particularly useful when factors associated with HIV
transmission and acquisition shift over time, such that groups
currently at risk for infection (eventual “incident cases”)
have different behavioral, demographic or other
characteristics from those with LTI [25, 26]. To date, few
studies have evaluated STARHS from the perspective of
epidemiologic utility. Instead, studies have focused on
assessing assay validity, concluding that STARHS assays
tend to misclassify certain individuals with LTI as RI [12,
17, 27-36]. At the population level, this often results in an
overestimation of HIV incidence rates relative to
prospectively observed seroconversion rates [18]. However,
from an epidemiologic standpoint, a certain degree of
assay/outcome misclassification may be less problematic.
For example, an assay or algorithm that misclassifies certain
individuals and overestimates HIV incidence can still be
considered epidemiologically useful if associations and
inference related to risk factors are not appreciably altered.
We conducted a combined cross-sectional survey (with
STARHS testing) and prospective cohort study of female sex
workers (FSW) at Projet Ubuzima in Kigali, Rwanda. An indepth analysis of the validity of STARHS-based incidence
estimates in this population was reported separately, and
found that HIV incidence rate estimates derived via the BED
assay alone and BED combined with Ax-AI were similar to
those based on prospective observation of HIV
seroconversion [24]. However, incidence rate estimates
derived via Ax-AI alone were substantially higher than those
based on observed HIV seroconversion. The present analysis
focused on risk factor estimation using STARHS plus
behavioral interview data. Risk factor estimates (adjusted
odds ratios) were compared for: 1) prevalent HIV infection;
2) RI based on three different STARHS RI classifications
(BED alone, Ax-AI alone, BED/Ax-AI combined) with CD4
correction (<200 cells/μl excluded from RI); and 3) observed
HIV seroconversion in the prospective study.
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study if they were: 18 years; at high risk for sexual
exposure to HIV, defined as having exchanged sex for
money at least once in the last month and/or currently having
sex with multiple partners plus having sex at least twice per
week (all enrolled women self-reported sex work); HIV
serostatus unknown or last test negative; and willing and able
to provide written informed consent.
Of 608 women identified as HIV-uninfected during the
cross-sectional survey, 397 (65%) who consented and were
not pregnant were enrolled consecutively into a prospective
cohort study. Cohort participants returned for five visits over
two years for HIV counseling and testing (including condom
provision), pregnancy and HSV-2 testing, and face-to-face
interviewing. Twelve-month retention was 96%, and median
follow-up was 689 days (range: 0-836). Specimens from
women who became HIV infected during follow-up were
tested by CD4 cytometry. Women who tested positive for
HIV, HSV-2 or pregnancy were referred for care and
treatment. All HIV-positive study participants were ARTnaïve.
The study was approved by the National Ethics
Committee and National HIV/AIDS Committee (CNLS) in
Rwanda, and by Columbia University Medical Center’s
Institutional Review Board in the United States.
Laboratory Assessments
Blood specimens were tested for HIV by First Response
(Premier Medical Corporation, India) and Uni-Gold (Trinity
Biotech Plc, Ireland) rapid tests, with Capillus HIV-1/HIV-2
Rapid Test (Trinity Biotech Plc, Ireland) as a tie-breaker.
HIV rapid test-positive results were confirmed by Murex
HIV Ag/Ab Combination ELISA (Abbott Laboratories,
Germany), and then tested further by CD4 cytometry at
Rwanda’s national reference laboratory in Kigali. HSV-2
infection was assessed by HerpeSelect 2 ELISA (Focus
Technologies, USA) and pregnancy by the Fortress hCG test
(Fortress Diagnostics, UK). HSV-2, pregnancy, HIV rapid
and ELISA testing was done onsite at Projet Ubuzima.

MATERIALS AND METHODOLOGY

Blood specimens from HIV-positive survey participants
were tested by the BED and Ax-AI assays. BED testing was
performed onsite following standard procedures as described
in the literature [23, 24] and manufacturer’s package insert
(Calypte® Biomedical Corporation, Oregon, USA), using a
cutoff of OD-n 0.8 to indicate RI. Ax-AI testing was
performed by the Pediatric HIV Research Unit in South
Africa using an unmodified AxSYM HIV-1/2gO ELISA
(Abbott, USA), and following procedures described in the
literature [13], with an avidity index 0.85 indicating RI
(Ax-AI cutoff based on personal communication with B.
Suligoi).

Study Design and Procedures

STATISTICAL METHODS

The study was conducted by Projet Ubuzima, a nongovernmental medical research organization in Kigali,
Rwanda. Between October 2006 and August 2007, 800
women participated in the cross-sectional survey with HIV,
HSV-2 and pregnancy testing. Individuals testing HIV
positive were further tested with the BED and Ax-AI assays,
and CD4 cytometry. All women underwent a face-to-face
interview for demographic and behavioral risk factor
information. Women were eligible for the cross-sectional

Outcome Definitions
In the cross-sectional sample, a prevalent HIV case was a
participant who tested positive on HIV rapid tests (with
ELISA confirmation), irrespective of STARHS results.
Prevalent cases represent undiagnosed HIV infections only
in the sampled population, given the eligibility criterion of
having an unknown HIV serostatus or a negative last HIV
test. In analyses of BED and Ax-AI separately, RI cases
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were HIV-positive participants who were classified as RI by
the BED or Ax-AI, respectively. In analyses using BED and
Ax-AI combined, we counted as RI cases only those survey
participants who tested HIV positive and were then classified
as RI by both BED and Ax-AI assays. Additionally,
individuals with CD4<200 cells/μl were considered probable
LTI cases regardless of STARHS results, and so individuals
classified as RI but with CD4<200 cells/μl were removed
from analyses of recent infection [37], but examined in
sensitivity analyses. In the prospective sample, HIV
seroconversion date was estimated as the midpoint between
the last negative and first positive HIV test (±3-month
interval).
Analysis
For the cross-sectional sample, odds ratios (OR) and 95%
confidence intervals (CI) for prevalent HIV (based on HIV
rapid testing), and for RI (based on STARHS classifications)
were derived from logistic regression models, with HIVnegative participants as the comparison group for each. All OR
are age-adjusted, and factors with P<0.05 were considered
statistically significant.
For the prospective sample, Cox proportional hazards
regression was used to estimate hazard ratios (HR) and 95%
CI for HIV seroconversion. Only results for baseline
covariates are presented to enable comparison with logistic
models for the cross-sectional sample. All HR are ageadjusted, and factors with P<0.05 were considered
statistically significant.
We qualitatively compared the direction, magnitude, and
statistical significance of putative risk factors for: 1)
prevalent HIV; 2) RI based on three different STARHS
classifications (BED alone, Ax-AI alone, and BED/Ax-AI
combined); and 3) prospectively observed seroconversion in
the cohort study. All statistical tests are two-sided. Data were
analyzed using SAS, version 9.2 (SAS Institute, Inc., Cary,
NC).
RESULTS
Sociodemographics
HIV-positive survey participants (N=192), HIV-negative,
non-enrolled survey participants (N=211), and prospective
cohort participants (N=397) were similar on most
sociodemographic characteristics (Table 1). Median age in
the three groups was 27 (IQR: 23-32), 25 (23-31), and 24
(22-28), respectively. Approximately one-fifth of
participants in all groups (23%, 17%, and 22%) had no
formal schooling. Most participants (93%, 91%, and 91%)
reported currently using at least one contraceptive method,
with about three-quarters (72%, 72%, and 75%) reporting
condom use by their last sex partner. The majority of women
in the three groups had 1-2 pregnancies during their
lifetimes. The proportion currently breastfeeding varied
across the groups (21%, 45% and 55%).
Prevalent, Recent, and Incident HIV Infections
In the cross-sectional survey, 192 women tested HIV
positive for a prevalence of 24.0% (95% CI, 21.0-27.0).
Among 190 prevalent HIV cases with BED/Ax-AI results,
36 (19%) were classified as RI by BED, and 56 (30%) as RI
by Ax-AI. Twenty-three participants (12%) were classified

Braunstein et al.

as RI by both assays; 121 (64%) as LTI by both assays; and
46 (24%) were classified discordantly on the assays (i.e.,
recent on BED and long-term on Ax-AI, or vice versa). Two
individuals concordant for RI on the assays (9%) had
CD4<200 cells/μl, indicating possible LTI. Nineteen of the
397 cohort participants (5%) seroconverted for HIV during
686.5 person-years of follow-up (2.8 per 100 person-years).
Risk Factors for Prevalent and Recent HIV Infection in
the Cross-Sectional Sample
Table 2 presents age-adjusted odds ratios (aOR) for putative
risk factors in the cross-sectional sample for prevalent HIV
infection (by HIV rapid testing and ELISA), and recent
infection (by STARHS assays, alone or in combination),
compared to HIV-negative participants. Only number of sex
partners in the prior 3 months (60-75 versus 76-120, aOR 5.1,
95% CI (1.0, 25.1)) was associated with RI (by BED/Ax-AI
combined), but not prevalent HIV infection. Two factors—
HSV-2 co-infection and having recently sought treatment for a
sexually transmitted infection (STI)—were positively associated
with both prevalent infection (aOR 8.4 (4.8, 14.7) and 2.1 (1.3,
3.3), respectively) and RI by BED/Ax-AI combined (aOR 17.9
(2.4, 134.7), and 3.9 (1.4, 10.4), respectively). Several factors
were associated (either positively or negatively) with prevalent
HIV, but not RI (by BED/Ax-AI combined), including: history
of forced sex (aOR 2.2 (1.5, 3.1)); current breastfeeding (aOR
0.3 (0.2, 0.4)); being widowed (aOR 1.7 (1.0, 2.8)); lifetime
HIV testing history (2 tests versus none, aOR 0.3 (0.2, 0.5); 1
test versus none, aOR 0.6 (0.4, 0.9)); regular alcohol
consumption (aOR 1.5 (1.1, 2.2)); and history of imprisonment
(aOR 1.8 (1.3, 2.6)). Education level, number of lifetime
pregnancies, condom use, frequency of vaginal sex, and marital
status were not significantly associated with prevalent or recent
HIV infection.
Table 2 also presents risk factors for recent HIV infection
on the BED and Ax-AI assays analyzed separately. HSV-2
seropositivity and recent STI treatment were consistently
identified as risk factors in both models. However, the AxAI method identified two additional factors—district of
residence and HIV testing history (2 times versus never)—
that were not significant in the BED model. Risk factor
associations for LTI, which excludes recent infections, and
prevalent HIV, which includes RI, were nearly identical to
one another (data not shown).
Comparison of Risk Factors Associated with STARHS
Results to those Identified via Prospectively Observed
Seroconversion
In the prospective cohort, having been HIV tested 2
times versus never in one’s lifetime and HIV testing within
the past 6 months were positively associated with HIV
seroconversion (Table 2). Having had two versus 4 lifetime
pregnancies was borderline statistically significant (aOR 8.0
(1.0, 65.4), P=0.05). None of the risk factors for prospective
seroconversion was also identified as a risk factor for RI (by
BED/Ax-AI combined) in the cross-sectional sample.
DISCUSSION
In these samples of urban Rwandan FSW, we found
mixed agreement between three different methods of
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Demographic and Behavioral Characteristicsa of Female Sex Workers in Kigali, Rwanda
HIV-Positive Cross-Sectional HIV-Negative, Non-Enrolled
Prospective Cohort Participants
Survey Participants
Survey Participants
(N=397)
(N=192)
(N=211)
N (%)
N (%)
N (%)

Median age, in years (IQR)***
Age groups: *
18-24

27.0 (23-32)

25.0 (23-31)

24.0 (22-28)

66 (34)

86 (41)

199 (50)

25-29
30-34

52 (27)
41 (21)

63 (30)
29 (14)

116 (29)
48 (12)

35

33 (17)

33 (16)

32 (8)

45 (23)

35 (17)

87 (22)

77 (40)
48 (25)

97 (46)
46 (22)

158 (40)
111 (28)

22 (12)

31 (15)

41 (10)

Education level: *
No formal schooling
Some primary school
Completed primary school
Secondary school (partial or completed)
b

Median weekly income in Rwandan francs (IQR)***

15,000 (8,000-23,000)

20,000 (12,000-33,000)

12,000 (7,000-20,000)

Currently using family planning method

179 (93)

191 (91)

362 (91)

Lifetime no. pregnancies
None
1

14 (7)
52 (27)

14 (7)
60 (29)

28 (7)
119 (30)

2
3

52 (27)
34 (18)

57 (27)
36 (17)

113 (29)
77 (19)

4

39 (20)

43 (21)

60 (15)

40 (21)

95 (45)

219 (55)

0
24 (13)

0
40 (19)

4 (1)
55 (14)

Currently breastfeeding*
c

Marital status :
Married (legal or common-law marriage)
Divorced/separated*
Widowed

37 (19)

22 (10)

34 (9)

Never married*
Currently have steady partnerd***

130 (68)
62 (32)

148 (70)
92 (44)

303 (76)
122 (31)

At last sexc:
Received money or gift from partner**

179 (93)

191 (91)

374 (94)

Partner used a condom
Used vaginal lubricant**

138 (72)
8 (4)

151 (72)
23 (11)

296 (75)
26 (7)

Vaginal cleansing beforehand

100 (52)

76 (36)

172 (43)

No. vaginal sex acts in last month
<20

31 (16)

32 (15)

73 (18)

20-39

57 (30)

52 (25)

120 (30)

40-59
60-89

42 (22)
45 (23)

54 (26)
52 (25)

81 (20)
78 (20)

90

17 (9)

21 (10)

45 (11)

No. sex partners in last 3 months
3-30

22 (12)

8 (4)

41 (10)

31-59

25 (13)

28 (13)

68 (17)

60-75
76-120

37 (19)
34 (18)

25 (12)
48 (23)

59 (15)
81 (21)

121

74 (39)

102 (48)

146 (37)

No. clients per week in last month
<5

32 (17)

31 (15)

87 (22)

5-9

59 (31)

53 (25)

104 (26)

10-15
16-25

52 (27)
39 (20)

66 (31)
42 (20)

110 (28)
66 (17)

>25

10 (5)

19 (9)

30 (8)
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(Table 1) contd…..

HIV-Positive Cross-Sectional HIV-Negative, Non-Enrolled
Prospective Cohort Participants
Survey Participants
Survey Participants
(N=397)
(N=192)
(N=211)
N (%)
N (%)
N (%)
No. years working as sex worker*
1

43 (22)

45 (21)

89 (22)

2
3

16 (8)
44 (23)

30 (14)
36 (17)

86 (22)
77 (19)

4-5
6

35 (18)
54 (28)

48 (23)
52 (25)

70 (18)
75 (19)

Ever had forced sex**

72 (38)

55 (26)

76 (19)

No. lifetime HIV tests (IQR)
Never tested

97 (51)

72 (34)

119 (30)

Once

64 (33)

81 (39)

137 (35)

Twice
3-5 times

20 (10)
9 (5)

57 (27)
0

67 (17)
60 (15)

6 times

2 (1)

0

13 (3)

4 (2)

22 (11)

57 (15)

 1 Genital symptom in past month

50 (26)

50 (24)

78 (20)

Sought treatment for STI symptom in last 3 months

34 (18)

22 (10)

32 (8)

Drink alcohol regularly
Have sex with clients who have consumed alcohol

120 (63)
185 (97)

119 (56)
196 (93)

203 (51)
371 (94)

Ever imprisoned

89 (47)

77 (37)

150 (38)

HIV testing in the last 6 months
e

Abbreviations: IQR = Inter-quartile range ; HIV = Human Immunodeficiency Virus; STI = Sexually transmitted infections.
*P < 0.05; **P < 0.01; ***P < 0.001 for comparisons between cohort participants and HIV-negative, non-enrolled survey participants.
a
Sample sizes for different questions may vary slightly from N=800 based on missing responses.
b
1 US Dollar=approximately 555 Rwandan francs.
c
Multiple responses allowed.
d
A steady partner is a regular sex partner with whom the woman has sex more often than with other partner(s), but does not live with and is not married to.
e
Includes: genital itching, burning, rash, pain; abnormal vaginal discharge, odor, or bleeding (non-menstrual); pain or difficulty urinating; genital ulcers, sores or blisters; pain during
sex; acute lower abdominal pain; other genital symptoms.

assessing risk factors for HIV infection, even when the HIV
incidence rates based on BED alone, BED/Ax-AI combined,
and observed seroconversion were relatively similar [24].
We identified a number of putative and protective risk
factors for prevalent HIV infection using conventional
serologic testing. We identified only a few risk factors for
recent infection using two STARHS assays (BED and AxAI) with three different classifications. Although two of the
three factors (HSV-2 coinfection and recent STI treatment)
were also risk factors for prevalent infection, the third factor
(number of sex partners in the past 3 months) was only
identified by the STARHS classification that best classified
recent HIV infection in this sample [24], the BED/Ax-AI
combined. Finally, risk factors for recent infection (by single
or combined STARHS assays) were different from those
associated with HIV seroconversions in the prospective
cohort.
Decisions by ministries of health to institutionalize the
use of STARHS for incidence surveillance—specifically, to
generate HIV incidence estimates and identify risk factors
for recently acquired infection from cross-sectional samples
in settings such as Kigali, Rwanda—hinge on the
epidemiologic utility of the approach. We defined
epidemiologic utility, in part, as the ability of an assay or
algorithm to distinguish risk factors for recent from longerterm infection when such differences exist. From the

perspective of epidemiologic utility, factors associated with
prevalent infection differed substantially from those
associated with recent infection in this sample.
Our findings are consistent with at least two plausible
scenarios in this specific population of Rwandan female sex
workers. First, in reality, there may be differences between
factors associated with incident versus prevalent HIV
infection in this population, for example if HIV transmission
dynamics in this group have recently begun to evolve.
Alternatively, true similarities in the risk factor profile for
incident and prevalent infection in this population could have
been masked in our analyses by misclassification on the
assays or low statistical power to identify risk factors as
statistically significant. However, prevalent infections, recent
infections by STARHS, and prospectively observed
seroconversions measure varying stages of infection in
different time periods, and so risk factors could be expected
to be different when the epidemic is evolving. Nonetheless,
the use of epidemiologic utility, including assay sensitivity
and specificity, as a metric of STARHS is conceptually and
methodologically important, particularly given the intent to
use STARHS as an epidemiological tool at the population
level, not at the individual level [38]. Future studies, ideally
with more statistical power, are needed to further examine
the epidemiologic utility among at-risk sub-Saharan African
populations.
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Risk Factors for Prevalent HIV Infection, Recent HIV Infectiona (by BED-CEIA Assay and Ax-AI, Separately and
Combined) and HIV Seroconversion in a Sample of ART-Naïve, Rwandan Female Sex Workers
Prevalent HIV
(N=192)

RI by BED Alone
(N, RI=31)

RI by Ax-AI Alone
(N, RI=50)

RI by BED and
Ax-AI Combined
(N, RI=21)

HIV Seroconversion
(Cohort N=397)

Age-Adjusted OR
(95% CI)

Age-Adjusted OR
(95% CI)

Age-Adjusted OR
(95% CI)

Age-Adjusted OR
(95% CI)

Age-Adjusted HR
(95% CI)

Age group:
18-24
25-29
30-34
35

0.8 (0.5, 1.2)
--REF-1.9 (1.2, 3.1)
1.8 (1.1, 3.0)

1.3 (0.5, 3.5)
--REF-2.0 (0.6, 6.9)
3.3 (1.1, 10.2)

1.1 (0.5, 2.2)
--REF-1.8 (0.7, 4.5)
1.9 (0.7, 4.8)

1.1 (0.4, 3.1)
--REF-0.8 (0.2, 4.1)
0.9 (0.2, 4.8)

1.0 (0.3, 3.1)
--REF-1.9 (0.6, 6.2)
undefined

District of residence:
Nyarugenge
Gasabo
Kicukiro

--REF-2.0 (1.3, 3.0)
3.1 (2.0, 4.8)

-- REF -2.2 (0.9, 5.4)
1.8 (0.6, 4.9)

-- REF -2.4 (1.1, 5.3)
3.2 (1.4, 7.2)

-- REF -2.1 (0.7, 6.2)
1.8 (0.5, 6.0)

-- REF -0.7 (0.2, 2.1)
1.1 (0.4, 3.4)

Education level:
No formal schooling
Some primary school
Completed primary school
Secondary school (some/completed)

--REF-0.9 (0.6, 1.4)
0.8 (0.5, 1.3)
0.7 (0.4, 1.3)

--REF-1.5 (0.5, 4.4)
1.1 (0.3, 3.5)
1.6 (0.4, 5.6)

--REF-1.1 (0.5, 2.4)
1.1 (0.5, 2.7)
1.4 (0.5, 3.8)

--REF-1.8 (0.5, 6.5)
1.3 (0.3, 5.4)
1.1 (0.2, 6.4)

--REF-0.9 (0.3, 2.9)
2.5 (0.6, 10.2)
undefined

Lifetime no. pregnancies:
None
1
2
3
4

1.9 (0.9, 4.2)
1.5 (0.9, 2.7)
1.5 (0.8, 2.5)
1.1 (0.6, 1.9)
--REF--

0.9 (0.2, 4.8)
0.3 (0.1, 1.3)
1.2 (0.4, 3.4)
0.8 (0.3, 2.4)
--REF--

1.9 (0.5, 6.7)
0.9 (0.3, 2.7)
1.4 (0.5, 3.5)
0.9 (0.3, 2.4)
--REF--

0.9 (0.1, 5.7)
0.2 (0.1, 1.3)
1.0 (0.3, 3.9)
0.8 (0.2, 3.3)
--REF--

undefined
1.2 (0.1, 14.7)
8.0 (1.0, 65.4)
4.7 (0.5, 41.1)
--REF--

Currently breastfeeding

0.3 (0.2, 0.4)

0.8 (0.4, 1.8)

0.7 (0.3, 1.5)

0.9 (0.4, 2.1)

1.6 (0.6, 4.3)

Marital status :
Currently have steady partnerd
Divorced/separated
Widowed
Never married

0.9 (0.7, 1.3)
0.7 (0.4, 1.1)
1.7 (1.0, 2.8)
1.0 (0.7, 1.4)

0.8 (0.4, 1.7)
0.9 (0.3, 2.5)
1.3 (0.4, 4.0)
0.9 (0.4, 2.2)

1.1 (0.6, 1.9)
0.7 (0.3, 1.7)
1.5 (0.6, 3.7)
1.1 (0.5, 2.2)

1.1 (0.5, 2.8)
1.0 (0.3, 3.4)
1.2 (0.2, 5.8)
1.0 (0.3, 3.0)

0.6 (0.2, 1.8)
0.5 (0.1, 4.2)
undefined
2.1 (0.6, 7.5)

At last sexc:
Received money/gift from partner
Partner used a condom
Vaginal cleansing beforehand

1.1 (0.6, 2.1)
0.9 (0.6, 1.3)
1.6 (1.2, 2.2)

1.1 (0.3, 4.8)
0.6 (0.3, 1.4)
1.5 (0.7, 3.1)

1.1 (0.3, 4.8)
1.2 (0.6, 2.5)
1.6 (0.9, 2.8)

0.7 (0.2, 3.2)
0.4 (0.2, 1.1)
1.9 (0.8, 4.6)

1.1 (0.2, 8.1)
1.0 (0.9, 1.1)
0.8 (0.3, 1.9)

No. vaginal sex acts in past month:
<20
20-39
40-59
60-89
90

0.7 (0.4, 1.3)
1.0 (0.6, 1.5)
1.0 (0.6, 1.6)
--REF-0.8 (0.4, 1.5)

1.7 (0.5, 6.1)
2.7 (0.9, 8.4)
1.5 (0.4, 5.6)
--REF-0.5 (0.1, 4.6)

0.8 (0.3, 1.9)
1.1 (0.5, 2.3)
0.8 (0.4, 2.0)
--REF-0.5 (0.1, 1.9)

2.3 (0.4, 13.0)
3.6 (0.8, 16.6)
1.9 (0.4, 10.7)
--REF-1.0 (0.1, 11.1)

0.4 (0.1, 1.4)
0.4 (0.1, 1.6)
0.2 (0.02, 1.4)
--REF-1.1 (0.2, 6.2)

No. sex partners in last 3 monthse:
3-30
31-59
60-75
76-120
121

1.3 (0.7, 2.4)
0.9 (0.5, 1.6)
1.5 (0.9, 2.5)
--REF-1.0 (0.6, 1.6)

3.2 (0.9, 11.7)
1.5 (0.4, 5.9)
2.7 (0.8, 9.4)
--REF-1.0 (0.3, 3.3)

1.1 (0.3, 3.7)
1.2 (0.5, 3.4)
2.2 (0.9, 5.6)
--REF-1.1 (0.4, 2.5)

3.5 (0.6, 21.5)
2.6 (0.5, 14.5)
5.1 (1.0, 25.1)
--REF-0.9 (0.6, 1.4)

2.6 (0.8, 8.7)
1.3 (0.4, 3.5)

No. clients per week in last month:
<5
5-9
10-15
16-25
>25

0.7 (0.4, 1.2)
1.1 (0.7, 1.8)
0.9 (0.6, 1.5)
--REF-0.6 (0.3, 1.4)

1.7 (0.5, 5.9)
2.2 (0.7, 7.1)
1.0 (0.3, 3.7)
--REF-0.6 (0.1, 5.7)

0.8 (0.3, 2.0)
1.3 (0.6, 2.9)
0.7 (0.3, 1.7)
--REF-0.7 (0.2, 2.8)

2.1 (0.4, 11.2)
3.1 (0.7, 14.7)
1.2 (0.2, 6.9)
--REF-1.1 (0.1, 12.8)

0.5 (0.1, 1.6)
0.6 (0.2, 2.2)
0.5 (0.1, 2.3)
--REF-undefined

Risk Factor

b

c

--REF-undefined
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(Table 2) contd…..

Prevalent HIV
(N=192)

RI by BED Alone
(N, RI=31)

RI by Ax-AI Alone
(N, RI=50)

RI by BED and
Ax-AI Combined
(N, RI=21)

HIV Seroconversion
(Cohort N=397)

Age-Adjusted OR
(95% CI)

Age-Adjusted OR
(95% CI)

Age-Adjusted OR
(95% CI)

Age-Adjusted OR
(95% CI)

Age-Adjusted HR
(95% CI)

No. years working as sex workerf:
1
2
3
4-5
6

1.0 (0.6, 1.7)
0.4 (0.2, 0.8)
1.2 (0.7, 1.9)
0.8 (0.5, 1.4)
--REF--

1.9 (0.7, 5.6)
0.8 (0.2, 2.8)
0.6 (0.1, 2.3)
0.8 (0.3, 2.6)
--REF--

1.5 (0.7, 3.6)
0.3 (0.1, 1.1)
1.0 (0.4, 2.6)
0.7 (0.2, 1.7)
--REF--

4.2 (0.9, 19.4)
1.0 (0.1, 6.9)
1.9 (0.3, 10.7)
1.4 (0.2, 8.8)
--REF--

1.8 (0.6, 5.3)
0.3 (0.1, 1.3)

Ever had forced sex

2.2 (1.5, 3.1)

1.7 (0.8, 3.7)

1.8 (1.0, 3.4)

2.3 (0.9, 5.7)

0.8 (0.2, 2.6)

Lifetime no. HIV tests
None
1
2

--REF-0.6 (0.4, 0.9)
0.3 (0.2, 0.5)

--REF-0.6 (0.3, 1.5)
0.6 (0.3, 1.5)

--REF-0.6 (0.3, 1.2)
0.4 (0.2, 0.9)

--REF-0.6 (0.2, 1.9)
1.1 (0.4, 3.0)

--REF-4.8 (0.6, 41.2)
12.9 (1.7, 98.9)

HIV tested in last 6 months

0.2 (0.1, 0.4)

0.2 (0.1, 1.8)

0.1 (0.01, 1.0)

0.3 (0.04, 2.2)

3.4 (1.2, 9.1)

Sought STI treatment in last 3 months

2.1 (1.3, 3.3)

2.8 (1.2, 6.9)

3.1 (1.5, 6.2)

3.9 (1.4, 10.4)

0.6 (0.1, 4.3)

Drink alcohol regularly

1.5 (1.1, 2.2)

1.1 (0.5, 2.3)

1.3 (0.7, 2.3)

0.7 (0.3, 1.7)

1.3 (0.5, 3.3)

Ever imprisoned

1.8 (1.3, 2.6)

0.9 (0.4, 2.0)

1.2 (0.6, 2.2)

0.6 (0.2, 1.7)

1.4 (0.5, 3.5)

HSV-2 seropositive (baseline)

8.4 (4.8, 14.7)

3.9 (1.5, 10.5)

9.1 (3.2, 25.9)

17.9 (2.4, 134.7)

1.4 (0.5, 3.8)

Pregnant (baseline)

0.7 (0.3, 1.3)

0.8 (0.2, 3.5)

0.7 (0.2, 2.5)

1.1 (0.3, 5.0)

NA

Risk Factorb

--REF-undefined

Abbreviations: OR=odds ratio; HR=hazard ratio; CI=confidence interval; HIV=Human Immunodeficiency Virus; RI=recent infection; STI=sexually transmitted infection; NA=not
applicable.
Bolded effect estimates have P< 0.05.
a
Participants with CD4<200 removed from RI classification, considered probable long-term HIV infection.
b
Sample sizes for different questions may vary slightly from the total N based on missing responses.
c
Multiple responses allowed.
d
A steady partner is a regular sex partner with whom the woman has sex more often than with other sex partner(s), but does not live with and is not married to.
e
Categories for age-adjusted HR’s for prospective cohort are: 3-30; 31-75; and 76 partners (referent group is 76).
f
Categories for age-adjusted HR’s for prospective cohort are: 1; 2-3; and 4 years (referent group is 4).

We conducted a number of sensitivity analyses of our
data. Specifically, adjustment of STARHS results from
bivariable models with CD4 count data (with individuals
with CD4<200 cells/μl excluded as probable LTI) did not
change inference regarding the existence of associations for
specific risk factors. Additional sensitivity analyses (data not
shown) showed that excluding persons classified as RI with
CD4 counts up to 500 cells/μl did not alter risk factor
findings. Misclassification rates may change with different
study populations, for example a less healthy population
with a different CD4 count distribution; misclassification of
individuals with LTI and high CD4 counts is also possible.
In our study, it is possible that greater specificity in the risk
factor analysis from use of the BED and Ax-AI assays
combined reduced the potential impact of CD4 adjustment.
Indeed, the combined testing algorithm appeared to perform
better for risk factor identification in the cross-sectional
sample than the assays alone, particularly compared with the
Ax-AI method alone. For example, the two additional risk
factors for RI identified by the Ax-AI method alone were
identified as risk factors for prevalent infection, which
reflects the substantial misclassification of individuals with
longer-term infection as RI by the Ax-AI method in this
population [24]. CD4 adjustment may have a greater impact
in studies using only a single assay versus a combined
algorithm, and such studies should therefore conduct CD4

testing if possible. Finally, conducting STARHS studies
among treatment-naïve individuals will help avoid
misinterpretation of STARHS results with CD4 adjustment.
Comparison of the risk factors identified using the crosssectional methods against those identified using the goldstandard prospective method may aid the interpretation of
cross-sectional risk factor data, however caution when
making such a comparison is warranted. In this study, there
was no overlap between risk factors for recent infection in
the cross-sectional sample and predictors of HIV
seroconversion in the prospective sub-sample. Limited
statistical power for identifying significant factors could
have affected agreement between the methods, as there were
relatively few events in both the RI and seroconversion
models. However, important differences between the subsample of women who were eligible and agreed to
participate in the prospective cohort study and HIV-negative
survey participants not enrolled in the cohort may also
contribute to the discordance. For example, HIV-negative
cohort participants were younger, more likely to be
breastfeeding, less likely to have a history of forced sex, and
had more recently initiated sex work than HIV-negative nonenrolled women, all factors associated with HIV risk.
Furthermore, changes over time in cohort participants’ risk
level (for example, because of the effect of prevention
interventions or the Hawthorne effect), or unknown factors
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Comparison of Demographic and Risk Characteristics of HIV Seroconverters (N=19) and HIV-Negative Participants
(N=378), Prospective Cohort, Kigali, Rwanda
Seroconverters
(N=19)
N (%)

HIV-Negative
Cohort Participants
(N=378)
N (%)

25.0 (22-31)

24.0 (22-28)

8 (42)
5 (26)
6 (32)

191 (51)
111 (30)
74 (20)

Education level:
No school
Primary (some/completed)
Some secondary

4 (21)
11 (58)
4 (21)

83 (22)
258 (68)
37 (10)

Currently breastfeeding

12 (63)

207 (55)

Lifetime no. pregnancies:
None or 1
2
3
4

2 (11)
11 (58)
5 (26)
1 (5)

145 (38)
102 (27)
72 (19)
59 (16)

Male condom use at last sex

16 (84)

280 (74)

Current hormonal contraception use

5 (26)

67 (18)



Median age (IQR)
Age group, years:
18-24
25-29
30

1 Genital symptom in past month

6 (32)

72 (19)

No. vaginal sex acts in past month:
<20
20-39
40-59
60-89
90

6 (32)
4 (21)
1 (5)
5 (26)
3 (16)

67 (18)
116 (31)
80 (21)
73 (19)
42 (11)

No. sex partners in last 3 months:
3-30
31-75
76

4 (21)
6 (32)
9 (47)

37 (10)
121 (32)
218 (58)

No. clients per week in past month:
<5
5-9
10-15
16

6 (32)
4 (21)
2 (11)
7 (36)

81 (21)
100 (27)
108 (29)
89 (23)

No. years working as sex worker¥:
1
2-3
4

6 (35)
3 (18)
8 (47)

61 (17)
160 (45)
137 (38)

No. lifetime HIV tests:
Never tested
Once
Twice

1 (5)
5 (26)
13 (69)

118 (31)
132 (35)
127 (34)

HIV tested in prior 6 months

6 (32)

51 (14)

HSV-2 seropositive at baseline

12 (67)

202 (56)

269 (86-768)

NA

Median days from enrollment to seroconversion (range)

Abbreviations: IQR = Inter-quartile range; HIV = Human Immunodeficiency Virus; NA = Not applicable.

Includes: genital itching, burning, rash, pain; abnormal vaginal discharge, odor, or bleeding (non-menstrual); pain or difficulty urinating; genital ulcers, sores or blisters; pain during
sex; acute lower abdominal pain; other genital symptoms.
¥
2 participants missing response, N=17.
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causing misclassification on the assays, could also have
contributed to discordance between cross-sectional and
prospective risk factor findings. Most HIV seroconversions
in the cohort occurred early during follow-up, and women
who seroconverted differed from women who remained
HIV-negative during follow-up on several potentially
important factors. For example, seroconverters had spent
fewer years in sex work, reported more frequent sex, had
higher HSV-2 seroprevalence at baseline, and reported more
genital symptoms in the month prior to enrollment (Table 3).
Additional study limitations are noted. Due to sample size
(specifically, too few outcomes), we could only adjust for
age and thus were unable to conduct a full multivariate
analysis. This could have resulted in uncontrolled
confounding, complicating comparisons between prospective
and cross-sectional samples. Measurement error in covariates
and bias due to unmeasured confounding could have affected
risk factor findings.

improved validity, will strengthen the argument to
incorporate HIV incidence surveillance into routine HIV
surveillance.

This study also has several strengths and provides new
insights. The use of two STARHS assays contributed
important information about the assays’ combined and
individual performance in a high-prevalence population. The
combined cross-sectional and prospective design, and
extensive interview data, enabled in-depth exploration,
triangulation, and comparison of risk factors for prevalent
and recently acquired HIV infection in multiple samples.
This in turn allowed us to explore an important dimension of
the epidemiologic utility of HIV incidence assays, namely
risk factor detection. Finally, availability of CD4 count data
aided interpretation and enabled important sensitivity
analyses.

This work was supported by the International Partnership
for Microbicides, Inc., the European and Developing
Countries Clinical Trials Partnership (through a project
entitled: “Preparing for Phase III vaginal microbicide trials
in Rwanda and Kenya: Preparedness studies, capacity
building, and strengthening of medical referral systems”),
the United States Centers for Disease Control and
Prevention, and National Institutes of Health - Institutional
Training Grant. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of
the manuscript.

CONCLUSION
In this selected high-risk group, factors associated with
incident HIV infection appeared to differ from those
associated with prevalent infection. More studies evaluating
the ability of STARHS to detect risk factors when combined
with survey data, alongside the validity of STARHS-based
incidence estimates, are needed to further establish the
epidemiologic utility of the approach for incidence
surveillance. Such studies are especially needed in subSaharan Africa where there is very limited experience with
STARHS, and where the potential impact of an alternative to
prospective measurement of HIV incidence is greatest [5].
Specifically, such investigations should be conducted in
populations in which risk factors for HIV incidence and
prevalence are known or expected to differ, as well as
populations with more diversity in risk factors (e.g.,
population-based samples). Despite persisting concerns
about the validity of particular STARHS assays, the results
of this study underscore the potential value of the approach
in identifying and distinguishing groups in need of HIV
prevention services when combined with complementary
risk group and behavioral information.
Public health officials in Rwanda might consider
incorporating STARHS into the next Demographic and
Health Survey-Plus to conduct similar analyses on the
national level and across population groups, as has been
done successfully in Uganda [37] and South Africa [18].
Further evaluations of STARHS data in Rwanda and across
diverse settings, as well as development of assays with
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